Istituto Oncologico Veneto Irccs

This study tested whether adding the immunotherapy drug avelumab after standard treatment (surgery and chemotherapy) can help prevent breast cancer from coming back in people with high-risk triple negative breast cancer. About 474 participants who had already completed curative t…

This early-phase study tested adding the drug regorafenib to standard treatment (temozolomide with or without radiation) for people newly diagnosed with a specific type of aggressive brain cancer called MGMT-methylated glioblastoma. The main goal was to find the safest dose of re…

This study looked at how safe and effective the drug Cabozantinib is for people aged 70 and older with advanced kidney cancer. Researchers tracked side effects and tumor response in 100 participants. The goal was to see if this treatment is a good option for older patients who ha…

This study looked back at medical records of over 1,000 people with two rare, non-invasive breast conditions called florid and pleomorphic lobular carcinoma in situ. The goal was to understand how doctors currently diagnose and treat these conditions, since there are no standard …